Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bristol-Myers to...

    Bristol-Myers to license two drugs to Biogen, Roche

    Written by supriya kashyap kashyap Published On 2017-04-14T09:20:23+05:30  |  Updated On 14 April 2017 9:20 AM IST
    Bristol-Myers to license two drugs to Biogen, Roche

    Bristol-Myers Squibb Co said it would license two of its drugs to Biogen Inc and Roche Holding AG for an upfront fee of $470 million.


    Bristol will license its experimental neuro degenerative disorder drug, BMS-986168, to Biogen as a treatment for progressive supra nuclear palsy, which is characterized by brain cell damage.


    Biogen said the drug also had the potential for use in Alzheimer's disease.


    BMS-986089, Bristol's rare muscle-wasting disease drug, will be licensed by Roche for use in duchenne muscular dystrophy.


    Bristol, which will receive an upfront payment of $300 million from Biogen and $170 million from Roche, said it expects the deals to close in the second quarter.


    The deals come amid activist investor pressure. The Wall Street Journal reported in February that billionaire investor Carl Icahn had taken a stake in Bristol and saw the company as a possible takeover target.


    Bristol also added three directors to its board in February, a move supported by JANA Partners LLC, an activist investor building a stake in the company's stock.


    The drug maker has fallen behind Merck & Co Inc in the key field of immuno-oncology after its Opdivo drug failed to prolong survival in previously untreated patients with non-small cell lung cancer, the largest cancer market.

    Alzheimer's diseaseBiogenbrain cell damageBristol-MyersCarl Icahnneuro degenerative disorderRochesupra nuclear palsy
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok